BRIEF published on 06/10/2025 at 10:04, 1 year 3 months ago Virbac Announces Share and Voting Rights for May 2025 Euronext Paris Voting Rights Shares Financial Declaration VIRBAC
PRESS RELEASE published on 06/10/2025 at 09:59, 1 year 3 months ago Virbac : Declaration of the number of share and voting rights 05/2025 Declaration of the number of shares and voting rights for VIRBAC on Euronext Paris. Total voting rights: 12,705,976. Total shares: 8,390,660 as of May 31, 2025 Euronext Paris Voting Rights Shares Financial Market VIRBAC
BRIEF published on 05/26/2025 at 10:10, 1 year 3 months ago Terms and conditions of the VIRBAC General Assembly Documents Shareholder Vote General Assembly VIRBAC Video Broadcast
BRIEF published on 03/13/2025 at 18:50, 1 year 6 months ago Virbac publishes its consolidated accounts for 2024 Financial Audit 2024 Financial Transparency Consolidated Accounts VIRBAC
PRESS RELEASE published on 03/13/2025 at 18:45, 1 year 6 months ago Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2024
BRIEF published on 10/17/2024 at 17:50, 1 year 11 months ago Virbac: Positive financial results at the end of September Strategic Acquisitions Financial Growth VIRBAC 2024 Results Animal Market
BRIEF published on 10/03/2024 at 12:07, 1 year 11 months ago Virbac: Declaration on Shares and Voting Rights Euronext Paris Voting Rights Actions Financial Transparency VIRBAC
PRESS RELEASE published on 10/03/2024 at 12:02, 1 year 11 months ago Virbac : Declaration of the number of shares and voting rights 09/2024 Declaration of the number of shares and voting rights for VIRBAC on Euronext Paris, with total voting rights of 12,708,271 and total shares representing the share capital of 8,390,660 as of September 30, 2024 Euronext Paris Voting Rights Shares Financial Market VIRBAC
BRIEF published on 09/16/2024 at 14:05, 2 years ago Virbac corrects the amount of its share capital Share Capital Press Release Animal Health Correction VIRBAC
BRIEF published on 09/13/2024 at 17:50, 2 years ago Virbac announces the conditions of Sébastien Huron's departure Resignation Remuneration VIRBAC Sebastian Huron Non-competition Clause
Published on 09/17/2026 at 15:55, 6 hours 7 minutes ago Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 15:25, 6 hours 37 minutes ago AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare
Published on 09/17/2026 at 15:00, 7 hours 2 minutes ago Norsemont Hits 41 Meters of 4.59 g/t Gold as Phase 3 Drilling Continues to Expand the Choquelimpie System
Published on 09/17/2026 at 15:00, 7 hours 2 minutes ago ECC Ventures 4 Announces Termination of Agreement With Cambria Gold Mines Inc.
Published on 09/17/2026 at 14:50, 7 hours 12 minutes ago Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner
Published on 09/17/2026 at 19:00, 3 hours 2 minutes ago Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 3 hours 3 minutes ago EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 3 hours 37 minutes ago Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 3 hours 52 minutes ago A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 4 hours 16 minutes ago RBI categorically denies the allegations of short-seller report
Published on 09/17/2026 at 17:40, 4 hours 22 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 4 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 15 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
